A Study of AK-1286 in Patients With Advanced Solid Tumors
- First Posted Date
- 2025-01-16
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06779045
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
Phase 1
Not yet recruiting
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06662669
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 606
- Registration Number
- NCT06548347
A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT06343935
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06096974
- Locations
- 🇺🇸
The Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Huntsman Cancer Institute and Hospital, University of Utah, Salt Lake City, Utah, United States
A Study of HY-0102 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06094777
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of YL-17231 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06078800
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: PE0116,PE0105
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06026501
A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: YL-13027，Sintilimab
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT05457517
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT05429398
© Copyright 2025. All Rights Reserved by MedPath